Neurocrine biosciences announces new survey revealing need for routine screening and earlier diagnosis for people living with tardive dyskinesia

-- majority of individuals polled reported tardive dyskinesia negatively impacts their day-to-day ability to function, including individuals living with mild or moderate uncontrolled movements1 san diego , may 5, 2025 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix) today announced the release of findings from a new survey conducted by the harris poll highlighting the profound negative impact of tardive dyskinesia on patients and reinforcing the need for routine screening, earlier diagnosis and treatment. the findings revealed that 80% of people living with tardive dyskinesia surveyed wished they had been screened for the condition earlier, and 86% wished their provider had discussed available treatment options for their uncontrolled movements sooner.1*   the survey results come during tardive dyskinesia (td) awareness week, may 4-10.
NBIX Ratings Summary
NBIX Quant Ranking